Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
CATB Catabasis Pharmaceuticals, Inc. weekly Stock Chart
CATB [NASD]
Catabasis Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-2.65 Insider Own0.87% Shs Outstand11.44M Perf Week-4.12%
Market Cap74.47M Forward P/E- EPS next Y-2.44 Insider Trans0.00% Shs Float11.44M Perf Month25.19%
Income-25.70M PEG- EPS next Q-0.62 Inst Own43.50% Short Float5.36% Perf Quarter37.63%
Sales- P/S- EPS this Y59.40% Inst Trans- Short Ratio5.90 Perf Half Y-8.31%
Book/sh3.29 P/B1.98 EPS next Y-1.20% ROA-55.40% Target Price39.00 Perf Year9.78%
Cash/sh3.56 P/C1.83 EPS next 5Y- ROE-61.90% 52W Range4.02 - 9.76 Perf YTD10.15%
Dividend- P/FCF- EPS past 5Y17.10% ROI- 52W High-33.30% Beta1.78
Dividend %- Quick Ratio7.70 Sales past 5Y- Gross Margin- 52W Low61.94% ATR0.38
Employees24 Current Ratio7.70 Sales Q/Q- Oper. Margin- RSI (14)57.18 Volatility6.68% 6.20%
OptionableYes Debt/Eq0.00 EPS Q/Q29.90% Profit Margin- Rel Volume1.36 Prev Close6.51
ShortableYes LT Debt/Eq0.00 EarningsFeb 06 BMO Payout- Avg Volume104.04K Price6.51
Recom1.00 SMA203.47% SMA5012.84% SMA2001.61% Volume0 Change0.00%
Oct-05-17Reiterated Oppenheimer Outperform $4 → $7
Feb-02-17Downgrade Citigroup Buy → Neutral
Dec-22-16Initiated H.C. Wainwright Buy $14
Jun-08-16Reiterated Wedbush Outperform $27 → $17
Jul-20-15Initiated Wedbush Outperform $27
Jul-20-15Initiated Oppenheimer Outperform $28
Jul-20-15Initiated Citigroup Buy $21
Jan-09-20 04:09PM  Catabasis (CATB) Partners with UK-Based Charity for DMD Study Zacks
Jan-08-20 08:00AM  Catabasis Pharmaceuticals and Duchenne UK Announce Partnership to Evaluate Edasalonexent in a Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial Business Wire
Dec-24-19 06:15AM  Is Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB) CEO Pay Fair? Simply Wall St.
Dec-23-19 02:15PM  Is Catabasis Pharmaceuticals Inc (CATB) A Good Stock To Buy? Insider Monkey +10.58%
Dec-16-19 08:00AM  Catabasis Pharmaceuticals Announces Phase 3 PolarisDMD Trial Enrolled Expected Patient Population Business Wire
Nov-25-19 06:45PM  Edited Transcript of CATB earnings conference call or presentation 7-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-18-19 06:53AM  Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
Nov-07-19 08:05AM  Catabasis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Reviews Business Progress Business Wire
Oct-24-19 08:00AM  Catabasis Pharmaceuticals to Present Third Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, November 7th Business Wire
Oct-19-19 09:26AM  Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB): When Will It Breakeven? Simply Wall St.
Oct-18-19 08:00AM  Catabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual Meeting Business Wire
Oct-05-19 08:00AM  Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy Business Wire
Sep-30-19 04:05PM  Catabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target Enrollment Business Wire
Sep-27-19 08:00AM  Catabasis Pharmaceuticals to Present the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the 24th International Congress of the World Muscle Society Business Wire
Sep-26-19 08:00AM  Catabasis Pharmaceuticals and the Jain Foundation Announce a Preclinical Research Collaboration to Study Edasalonexent in Dysferlinopathy Business Wire
Sep-25-19 08:00AM  Catabasis Pharmaceuticals Names Andrew A. Komjathy Chief Commercial Officer Business Wire
Sep-19-19 10:13AM  How Much Of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Do Institutions Own? Simply Wall St.
Aug-20-19 10:58AM  Investors Who Bought Catabasis Pharmaceuticals (NASDAQ:CATB) Shares Three Years Ago Are Now Down 87% Simply Wall St.
Aug-09-19 05:04PM  Edited Transcript of CATB earnings conference call or presentation 8-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-08-19 08:05AM  Catabasis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Reviews Business Progress Business Wire
Aug-07-19 08:00AM  Catabasis Pharmaceuticals Appoints Hugh M. Cole to its Board of Directors Business Wire
Aug-06-19 08:00AM  Catabasis Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference Business Wire
Jul-25-19 08:30AM  Catabasis Pharmaceuticals to Report Second Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, August 8th Business Wire
Jul-15-19 03:08PM  Does Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB) CEO Pay Reflect Performance? Simply Wall St.
Jun-27-19 08:00AM  Catabasis Pharmaceuticals Provides Update on Global Phase 3 PolarisDMD Trial for Edasalonexent at Parent Project Muscular Dystrophy 25th Annual Conference Business Wire
Jun-21-19 09:45AM  Catabasis Pharmaceuticals Presents Preclinical Data Showing Potential for Bone Preservation with Edasalonexent in Duchenne Muscular Dystrophy Business Wire
Jun-18-19 08:00AM  Catabasis Pharmaceuticals to Present at Upcoming Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy and Parent Project Muscular Dystrophy 25th Annual Conference Business Wire +6.61%
Jun-07-19 09:24AM  Vertex Expands Collaboration With CRISPR, Acquires Exonics Zacks
May-15-19 06:33PM  Edited Transcript of CATB earnings conference call or presentation 14-May-19 12:30pm GMT Thomson Reuters StreetEvents +7.46%
08:38AM  SV Life Sciences Advisers, LLC Buys Catabasis Pharmaceuticals Inc, Sells KalVista ... GuruFocus.com
May-14-19 08:05AM  Catabasis Pharmaceuticals Reports First Quarter 2019 Financial Results and Reviews Business Progress Business Wire
May-02-19 08:00AM  Catabasis Pharmaceuticals to Present Data from the MoveDMD® trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 71st Annual Meeting Business Wire
Apr-30-19 08:00AM  Catabasis Pharmaceuticals to Report First Quarter 2019 Financial Results and Recent Corporate Developments on Tuesday, May 14th Business Wire
Apr-26-19 03:26PM  Should You Be Concerned About Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB) Historical Volatility? Simply Wall St.
Apr-12-19 11:34AM  Top Ranked Momentum Stocks to Buy for April 12th Zacks
Apr-01-19 08:00AM  Catabasis Pharmaceuticals to Present at Upcoming Neuromuscular Translational Research Conference and MDA Clinical and Scientific Conference Business Wire
Mar-26-19 12:11PM  Proteostasis Plunges on Weak Data From Cystic Fibrosis Study Zacks
08:07AM  Will Catabasis Pharmaceuticals Continue to Surge Higher? Zacks
Mar-19-19 12:26PM  Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight Zacks
Mar-18-19 09:02AM  Rising P/E an Overlooked Criterion: 5 Top Stocks Zacks +9.54%
Mar-14-19 06:09PM  Edited Transcript of CATB earnings conference call or presentation 14-Mar-19 12:30pm GMT Thomson Reuters StreetEvents
08:30AM  Catabasis (CATB) Beats Earnings in Q4, Revenues Nil Zacks
08:05AM  Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Reviews Business Progress Business Wire
Mar-13-19 08:00AM  Catabasis Pharmaceuticals to Present at Oppenheimers 29th Annual Healthcare Conference Business Wire
Mar-08-19 09:54AM  Townsquare (TSQ) to Report Q4 Earnings: What's in the Cards? Zacks +7.77%
Mar-07-19 08:57AM  Athersys (ATHX) Q4 Earnings: What's in Store for the Stock? Zacks
08:51AM  Is a Beat in Store for Catabasis (CATB) This Earnings Season? Zacks
Mar-06-19 01:56PM  Investors Who Bought Catabasis Pharmaceuticals Shares Three Years Ago Are Now Down 93% Simply Wall St.
Feb-28-19 08:00AM  Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Developments on Thursday, March 14 Business Wire
Feb-19-19 08:00AM  Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy Business Wire +6.31%
Feb-14-19 08:00AM  Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors Business Wire
Feb-06-19 09:00AM  Catabasis Pharmaceuticals Announces Pricing of $20 Million Underwritten Public Offering Business Wire -23.64%
08:23AM  The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering Benzinga
Feb-05-19 04:01PM  Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering Business Wire
Jan-29-19 07:55AM  New Research: Key Drivers of Growth for Tiffany, CarMax, Cars, RPC, Cleveland-Cliffs, and Catabasis Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-15-19 11:10AM  Is Catabasis Pharmaceuticals, Inc.s (NASDAQ:CATB) CEO Overpaid Relative To Its Peers? Simply Wall St.
Jan-14-19 01:42AM  Catabasis Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Jan-11-19 09:30AM  Is Catabasis Pharmaceuticals (CATB) Outperforming Other Medical Stocks This Year? Zacks
Jan-08-19 08:38AM  Agenus (AGEN) Surges: Stock Moves 9.4% Higher Zacks
Jan-04-19 08:00AM  Catabasis Pharmaceuticals Appoints Gregg Lapointe to its Board of Directors Business Wire +8.04%
Jan-03-19 08:08AM  Catabasis Pharmaceuticals Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy Progress Update and Additional Trial Sites Open for Enrollment Business Wire
Dec-31-18 04:31PM  Why Canada Goose Holdings, Catabasis Pharmaceuticals, and Globalstar Jumped Today Motley Fool +7.13%
Dec-24-18 08:00AM  Catabasis Pharmaceuticals Announces Reverse Stock Split Business Wire -7.29%
Dec-18-18 08:12AM  Catella Divests Card Issuing Operations in Luxembourg to Advanzia Bank and Completes Strategic Review PR Newswire
Dec-12-18 02:22AM  Catella and Söderberg & Partners in Strategic Partnership PR Newswire
Nov-28-18 08:55AM  Consolidated Research: 2018 Summary Expectations for MyoKardia, Bristow Group, The Chefs' Warehouse, Catabasis Pharmaceuticals, Casa, and EP Energy Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-27-18 08:00AM  Catabasis Pharmaceuticals Announces Publication of Phase 1 Clinical Results of Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy Business Wire
Nov-16-18 05:48PM  Edited Transcript of CATB earnings conference call or presentation 13-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-15-18 09:26AM  Does The Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Share Price Fall With The Market? Simply Wall St.
Nov-13-18 08:15AM  Catabasis Pharmaceuticals: 3Q Earnings Snapshot Associated Press
08:05AM  Catabasis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Reviews Business Progress Business Wire
07:45AM  Catabasis Pharmaceuticals Announces Collaboration with the University of Texas Southwestern to Explore the Potential Benefits of Edasalonexent on Cardiac Function in Duchenne and Becker Muscular Dystrophies Business Wire
Nov-02-18 08:00AM  Catabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on PolarisDMD: Phase 3 Clinical Trial of Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy Business Wire
Oct-30-18 08:00AM  Catabasis Pharmaceuticals to Report Third Quarter 2018 Financial Results and Recent Corporate Developments on Tuesday, November 13 Business Wire
Oct-18-18 08:25AM  Recent Analysis Shows Progenics Pharmaceuticals, Catabasis Pharmaceuticals, Warrior Met Coal, Preformed Line Products, Express, and Sanmina Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire +8.39%
Oct-17-18 02:20PM  Flagship biotech startup leases space from struggling Catabasis American City Business Journals
Oct-04-18 09:20AM  Bet on Rising P/E Investing With These 5 Top-Ranked Stocks Zacks
Oct-03-18 08:00AM  Catabasis Pharmaceuticals Presents Data Supporting MRI T2 as a Potential Marker of Clinical Outcome in Duchenne Muscular Dystrophy at the World Muscle Society Congress Business Wire -8.53%
Sep-25-18 08:00AM  Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy Business Wire
Sep-19-18 08:00AM  Catabasis Pharmaceuticals to Present New Edasalonexent Clinical Results and Phase 3 Trial Design in Duchenne Muscular Dystrophy at the World Muscle Society Congress Business Wire +5.77%
Sep-13-18 09:13AM  Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study Zacks
Aug-27-18 07:45AM  Recent Analysis Shows KalVista Pharmaceuticals, IZEA, Sonic Automotive, Catabasis Pharmaceuticals, ANI Pharmaceuticals, and Clovis Oncology Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-09-18 09:48AM  Catabasis Pharmaceuticals: 2Q Earnings Snapshot Associated Press
08:05AM  Catabasis Pharmaceuticals Reports Second Quarter 2018 Financial Results and Reviews Business Progress Business Wire
06:30AM  Catabasis Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Aug-08-18 08:00AM  Catabasis Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference Business Wire +9.16%
Jul-26-18 08:00AM  Free Technical Insights on BioPharmX and Three Other Biotech Stocks ACCESSWIRE +6.01%
08:00AM  Catabasis Pharmaceuticals to Report Second Quarter 2018 Financial Results and Recent Corporate Developments on Thursday, August 9 Business Wire
Jul-09-18 08:00AM  Catabasis Pharmaceuticals Announces Plans for Edasalonexent Phase 3 POLARIS DMD Trial in Duchenne Muscular Dystrophy Business Wire
Jun-26-18 07:45AM  Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta Holding, and Seattle Genetics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-25-18 03:40PM  Catabasis Pharmaceuticals Presents New Edasalonexent Clinical Biomarker Data Showing NF-kB Inhibition and Target Engagement in the MoveDMD® Trial Business Wire
08:30AM  Catabasis Pharmaceuticals, Edasalonexent for the Treatment of Duchenne Muscular Dystrophy Showing Early Clinical Success ACCESSWIRE
Jun-22-18 04:05PM  Catabasis Pharmaceuticals Announces Closing of $42M Underwritten Public Offering Business Wire
Jun-20-18 09:10AM  Catabasis Pharmaceuticals Announces Pricing of $42 Million Underwritten Public Offering Business Wire -14.71%
Jun-18-18 08:00AM  Catabasis Pharmaceuticals to Present at Upcoming Scientific and Advocacy Conferences Business Wire -20.90%
Jun-06-18 12:58PM  Catabasis Pharmaceuticals Incs (NASDAQ:CATB) Path To Profitability Simply Wall St.
May-11-18 05:09PM  Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat Zacks
02:41PM  Edited Transcript of CATB earnings conference call or presentation 10-May-18 12:30pm GMT Thomson Reuters StreetEvents
09:42AM  Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss Zacks
05:59AM  Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up Zacks
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). It is also involved in developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD; and collaboration with the University of Texas Southwestern to study the potential benefits of edasalonexent treatment. The company also has a preclinical research collaboration with the Jain Foundation to study edasalonexent (CAT-1004) in Dysferlinopathy. The company was founded in 2008 and is based in Cambridge, Massachusetts.
open in yahoo | open in reuters | open in google